Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High – What’s Next?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $109.28 and last traded at $106.00, with a volume of 45395 shares traded. The stock had previously closed at $105.89.

Analysts Set New Price Targets

MIRM has been the subject of a number of recent analyst reports. Citizens Jmp increased their target price on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Royal Bank Of Canada initiated coverage on Mirum Pharmaceuticals in a report on Tuesday, February 17th. They issued an “outperform” rating and a $130.00 price target on the stock. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Morgan Stanley boosted their price target on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.17.

Mirum Pharmaceuticals Trading Down 0.3%

The business’s 50-day moving average price is $91.07 and its two-hundred day moving average price is $78.26. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market capitalization of $5.42 billion, a price-to-earnings ratio of -122.65 and a beta of 0.49.

Insider Transactions at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 2,631 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $271,782.30. Following the sale, the chief operating officer owned 20,655 shares in the company, valued at $2,133,661.50. The trade was a 11.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president directly owned 4,503 shares of the company’s stock, valued at $465,159.90. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 45,136 shares of company stock worth $4,352,029. 22.87% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of large investors have recently bought and sold shares of MIRM. Emerald Advisers LLC boosted its stake in Mirum Pharmaceuticals by 20.9% during the third quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals in the 3rd quarter valued at about $808,000. TimesSquare Capital Management LLC acquired a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $22,041,000. Candriam S.C.A. lifted its holdings in shares of Mirum Pharmaceuticals by 8.0% in the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after purchasing an additional 30,021 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in Mirum Pharmaceuticals during the third quarter worth $503,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.